Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

Jones, Courtney L., Stevens, Brett M., D'Alessandro, Angelo, Reisz, Julie A., Culp-Hill, Rachel, Nemkov, Travis, Pei, Shanshan, Khan, Nabilah +8 more·2018·Cancer Cell
DOI 10.1016/j.ccell.2018.10.005

Cited by (591)

Items 501–591 of 591

  1. ZDHHC21: a mitochondrial vulnerability in AML
    Aaron David Schimmer · 2023 · Blood
  2. Turning Down the Temperature on Leukemia Stem Cells
    Courtney L. Jones · 2023 · Cancer Research
  3. CD4 + T cell-derived IL21 regulates stem cell fate in acute myeloid leukemia by activation of p38-MAPK signaling
    Viviana Rubino, Michelle Hüppi, Sabine Höpner, Luigi Tortola, Lea Taylor, Irene Keller, Rémy Bruggmann, Marie-Noëlle Kronig, Ulrike Bacher, Manfred Köpf et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  4. BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia
    Laura López-Hernández, Stephanie J. Crowley, Sara Cea-Sánchez, Ricardo de Arellano, Neetij Krishnan, Patrick Toolan-Kerr, Lynn S. White, Domenico Ignoti, Emily Soto-Hidalgo, Stefano Gustincich et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Leukemia stem cell expansion cultures reveal clonal drivers of leukemogenesis and therapy response
    Indranil Singh, Andrea Polazzi, Alex Maya Pombo, Marta López-Osias, Celine Bauer, Maria Guarini, Pedro Sánchez-Sánchez, Luna Goulet, Carmen Gallardo, Daniel Fernández-Pérez et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  6. MDS Stem Cell Biology
    Matthew T. Villaume, Paul Brent Ferrell, Michael Robert Savona · 2020 · Springer eBooks
  7. Outfoxing OXPHOS: Amino Acid Metabolism and the Leukemia Stem Cell
    Kristen Marie O’Dwyer · 2019 · The Hematologist
  8. Antimetabolic cooperativity with the clinically approved kidrolase and tyrosine kinase inhibitors to eradicate cml stem cells
    Anne Trinh, Raeeka Khamari, Quentin Fovez, François‐Xavier Mahon, Béatrice Turcq, Didier Bouscary, Patrice Maboudou, Marie Joncquel-Chevalier Curt, Valérie Coiteux, Nicolas Germain et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  9. Amino Acid Metabolism in Acute Myeloid Leukemia
    Pascal Mossuz, Julie Mondet, Christabelle Rajesh · 2021 · Vide Leaf, Hyderabad eBooks
  10. Inhibition of pyrimidine biosynthesis targets protein translation in AML
    Joan So, Alexander Charles Lewis, Lorey K. Smith, Kym L. Stanley, Lizzy Pijpers, Pilar M. Domínguez, Simon J. Hogg, Stephin J. Vervoort, Ricky W. Johnstone, Gabrielle McDonald et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  11. A two-step in vivo CRISPR screen unveils pervasive RNA binding protein dependencies for leukemic stem cells and identifies ELAVL1 as a therapeutic target
    Ana Vujovic, Laura P. M. H. de Rooij, Ava Keyvani Chahi, He Tian Chen, Brian A. Yee, Sampath Kumar Loganathan, Lina Liu, Derek C.H. Chan, Amanda Tajik, Emily Tsao et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Three essays on licensing university inventions
    Radu Munteanu · 2007 · eScholarship (California Digital Library)
  13. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies
    Tariq I. Mughal, Naveen Pemmaraju, Rafael L. Bejar, Robert Peter Gale, Prithviraj Bose, Jean‐Jacques Kiladjian, Josef T. Prchal, Daniel J. Royston, Daniel Aaron Pollyea, Peter Valent et al. · 2022 · Hematological Oncology
  14. T-cell immunoglobulin mucin-3 expression in Acute Myeloid Leukemia: a cross-sectional study
    2019 · SECI Oncology Journal
  15. Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition
    Laleh S. Arabanian, Jenni Adamsson, Anke Unger, Raffaella Di Lucrezia, Tim Bergbrede, Arghavan Ashouri, Erik Larsson, Peter Nußbaumer, Bert Klebl, Lars Palmqvist et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Interpretable precision medicine for acute myeloid leukemia
    Marian Gimeno · 2023
  17. Advances in Targeted Therapy for Acute Myeloid Leukemia
    Toshihiro Miyamoto, Yoshikane Kikushige · 2022 · Nihon Naika Gakkai Zasshi
  18. Fueling fate: Metabolic crosstalk in the bone marrow microenvironment
    Livia E. Lisi-Vega, Simón Méndez‐Ferrer · 2023 · Advances in stem cells and their niches
  19. The potential use of recombinant immunotoxin and BCL-2 inhibitors for leukemic stem cell elimination
    Diondra Eka Rizkiawan · 2023 · World Journal of Advanced Research and Reviews
  20. Potential Correlation between Gene Mutations and Metabolic Changes in Acute Myeloid Leukemia
    Aili Jiang, Zhiying Hou, Bingyan Yu, Ning Wang, Bin Zhang · 2024 · The Natural Products Journal
  21. Additional file 6 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Yuan Tao, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  22. Additional file 3 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Tao, Yuan, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  23. Additional file 7 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Yuan Tao, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  24. Additional file 2 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Tao, Yuan, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  25. Additional file 5 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Yuan Tao, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  26. Additional file 4 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Miao Chen, Yuan Tao, Pengjie Yue, Guo, Feng, Xiaojing Yan · 2023 · Figshare
  27. Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition
    Laleh S. Arabanian, Jenni Adamsson, Anke Unger, Raffaella Di Lucrezia, Tim Bergbrede, Arghavan Ashouri, Erik Larsson, Peter Nußbaumer, Bert Klebl, Lars Palmqvist et al. · 2024 · eLife
  28. Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response
    Sarah J. Skuli, A’ishah Bakayoko, Marisa Kruidenier, Bryan Manning, Paige Pammer, Akmal Salimov, Owen Riley, Gisela Brake-Sillá, Michael Bowman, Leslie N. Martinez-Gutierrez et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  29. Mitohormesis : la clé de voûte de la résistance thérapeutique des cellules cancéreuses
    Emeline Boët, Estelle Saland, Sarah J. Skuli, Emmanuel Griessinger, Jean‐Emmanuel Sarry · 2024 · Comptes Rendus Biologies
  30. The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
    Shan Zheng, Yuxin Tong, Linlin Yang, Jiayi Chen, Yamin Tan · 2024 · Annals of Hematology
  31. LncRNA: Secret Regulators of Cancer Metabolism
    Durmus Burak Demirkaya, Serap Yalçın · 2024 · Interdisciplinary cancer research
  32. Stroma-driven horizontal transfer of TCA proteins mediates metabolic plasticity and imatinib resistance in leukemia
    Katarzyna Piwocka, Piotr Chrościcki, Nikodem Kasak, Dorota Dymkowska, Laura Turos-Korgul, Dominik Cysewski, Vira Chumak, Dawid Stępnik, Monika Kusio-Kobiałka, Magdalena Lebiedzińska et al. · 2025 · Research Square
  33. CD40 promotes AML survival via non-canonical NF-κB signaling and aberrant lipid metabolism
    Li Zhang, Xin Luo, Dongyan Wu, Qiang Zhou, Jiachun Qiu, Muxia Yan, Yiqian Wang · 2025 · International Immunopharmacology
  34. Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2
    Mark Jordan Althoff, Mohd Minhajuddin, Brett M. Stevens, Austin E. Gillen, Stephanie Gipson, Sweta B. Patel, Ian T. Shelton, Regan Miller, Ana Vujovic, Anna Krug et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition
    Laleh S. Arabanian, Jenni Adamsson, Anke Unger, Raffaella Di Lucrezia, Tim Bergbrede, Arghavan Ashouri, Erik Larsson, Peter Nußbaumer, Bert Klebl, Lars Palmqvist et al. · 2025 · eLife
  36. Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) regulates mitochondrial metabolism and chemotherapy resistance in acute myeloid leukemia (AML)
    Yijing Zhao, Hanfei Guo, Liting Niu, Jinfang Zhao · 2025 · Cancer Pathogenesis and Therapy
  37. MRC2 expression modulates metabolism in acute myeloid leukemia stem cells
    Taylor Mills, Marlon Arnone, Elsa Görsch, Simone Poeschel, Stefan Winter, Jessica Viola Kübler, Lucca M. Kimmich, Florian Büttner, Jan Frederic Weller, Saskia Rudat et al. · 2025 · Cancer Letters
  38. Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia
    Lauren Brakefield, Amit Budhraja, Peter A. Hall, Dixie Brewington, Jamila Moore, Josi Lott, Yonghui Ni, Dennis Voronin, Oliver Grant-Chapman, Tresor O Mukiza et al. · 2026 · Cell Death and Disease
  39. Additional file 1 of Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
    Cho, Hyunsoo, Jang, Ji Eun, Eom, Ju-In, Jeung, Hoi-Kyung, Haerim Chung, Kim, Jin Seok, Cheong, June-Won, Min, Yoo Hong · 2021 · Figshare
  40. Additional file 4 of Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
    Cho, Hyunsoo, Jang, Ji Eun, Eom, Ju-In, Jeung, Hoi-Kyung, Haerim Chung, Kim, Jin Seok, Cheong, June-Won, Min, Yoo Hong · 2021 · Figshare
  41. Additional file 1 of Construction and validation of a fatty acid metabolism risk signature for predicting prognosis in acute myeloid leukemia
    Chen, Miao, Yuan Tao, Yue, Pengjie, Guo, Feng, Yan, Xiaojing · 2023 · Figshare
  42. Additional file 3 of Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
    Cho, Hyunsoo, Jang, Ji Eun, Eom, Ju-In, Jeung, Hoi-Kyung, Haerim Chung, Kim, Jin Seok, Cheong, June-Won, Min, Yoo Hong · 2021 · Figshare
  43. Additional file 2 of Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
    Cho, Hyunsoo, Jang, Ji Eun, Eom, Ju-In, Jeung, Hoi-Kyung, Haerim Chung, Kim, Jin Seok, Cheong, June-Won, Min, Yoo Hong · 2021 · Figshare
  44. Additional file 1 of Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
    Ralf Buettner, Le Xuan Truong Nguyen, Corey James Morales, Chen, Min-Hsuan, Wu, Xiwei, Lisa S. Chen, Hoang, Dinh Hoa, Servando Hernandez Vargas, Vinod A. Pullarkat, Varsha V. Gandhi et al. · 2021 · Figshare
  45. Additional file 1 of A statistical network pre-processing method to improve relevance and significance of gene lists in microarray gene expression studies
    Giuseppe Agapito, Marianna Milano, Mario Cannataro · 2022 · Figshare
  46. Additional file 1 of The recombinant l-lysine α-oxidase from the fungus Trichoderma harzianum promotes apoptosis and necrosis of leukemia CD34 + hematopoietic cells
    Mariana do Nascimento Costa, Thiago Aparecido da Silva, Dimitrius Santiago P.S.F. Guimarães, Rafael Ricci-Azevedo, Felipe R. Teixeira, Silveira, Leonardo Reis, Gomes, Marcelo Damário, Faça, Vítor Marcel, Eduardo Brandt Oliveira, Calado, Rodrigo T. et al. · 2024 · Figshare
  47. Venetoclax‐Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview
    Yufeng Du, Mohammad Arian Hassani, Chunhong Li, Zhijia Zhao, Y Q Liu, Cheng-Tao Zhang, Jinsong Yan · 2025 · Cancer Reports
  48. Prediction of prognosis and immunotherapy response of tryptophan metabolism genes in acute myeloid leukemia
    Tan-Tan Zhong, Mei-Rui Zhang, Xinran Qi, Zhihui Qi, Li Peipei, Na Wang, Xianghua Wang, Panpan Feng, Xiaosheng Fang · 2026 · Frontiers in Pharmacology
  49. Clonal cacophony of AML relapse
    Eunice S. Wang · 2026 · Blood
  50. Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies
    B. M. R. Harvey, Anoop Kumar Enjeti, Danielle R. Bond, Heather J Lee · 2026 · Critical Reviews in Oncology/Hematology
  51. Identifying cancer cell-state transitions from multimodal single-cell data
    Guido Baselli, Alisa Alekseenko, Judit Liaño-Pons, Lefteris Sinanis, Eltjona Rrapaj, Marie Arsenian‐Henriksson, Vicent Pelechano · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  52. Protein S -acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells
    Nithya Balasundaram, Ayşegül Erdem, Azeem Sharda, Veerle W. Daniëls, Phillip L. Chea, Fleur Leguay, YOUZHONG LIU, Mark A. Keibler, Charles Vidoudez, Andrew A. Lane et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  53. Tuning mitochondrial fate to disarm leukemic stem cells
    Xufeng Chen · 2026 · Blood
  54. Etude in vivo de la chimiorésistance dans les leucémies aigues myéloïdes humaines
    Nesrine Aroua · 2018 · theses.fr (ABES)
  55. Reprogrammation métabolique dans les leucémies aigues myéloblastiques (LAM) : Impact clinique et mécanismes oncogéniques
    Caroline Lo Presti · 2020
  56. Nouvelles stratégies de sensibilisation des Cellules Souches Leucémiques en ciblant l’axe BCR-ABL/BMI1
    Fabien Muselli · 2020 · theses.fr (ABES)
  57. Overcoming drug resistance in diffuse large b-cell lymphoma by targeting cell metabolism and the alternative NF-kB pathway
    Stéphanie Nuan-Aliman · 2021 · theses.fr (ABES)
  58. Etude des adaptations métaboliques tissulaires et systémiques dans les leucémies aigues myéloides
    Guillaume Cognet · 2021 · theses.fr (ABES)
  59. Etude in vivo du rôle du métabolisme énergétique et mitochondrial dans la résistance thérapeutique des leucémies aiguës myéloïdes
    Claudie Bosc · 2020 · theses.fr (ABES)
  60. EVT-701 : targeting electron transport chain complex I as therapeutic approach in cancer
    Raquel Luna Yolba · 2021 · theses.fr (ABES)
  61. Prédire les effets anti-leucémiques du venetoclax dans les LAM et les optimiser en ciblant la mitophagie dépendante de PINK1
    Romain Vazquez · 2024 · theses.fr (ABES)
  62. Aging Is a Key Driver for Adult Acute Myeloid Leukemia
    Rong L. Yin, Haojian Zhang · 2026 · Aging and Cancer
  63. Dominant COSMIC Mutational Signatures and Unsupervised Machine Learning Define Mechanism-Based Therapeutic Stratification in Blast-Crisis CML: Implications in Precision Medicine of Relapsed and Refractory Cancers
    Zafar Iqbal, Abdulkareem Al-Garni, Yaqob Samir Taleb, Nasser Mohammed AlQahtani, Muhammad Farooq Sabar, Muhammad Alshuaibi, Essa Al Mansour, Mashael AlShuker, Tahani Alqurashi, Azfar Athar Ishaqui et al. · 2026 · Preprints.org
  64. PIEZO1 is Required for Acute Myeloid Leukemia Progression and Leukemia Stem Cell Maintenance via HIF1A‐SLC7A11 Axis‐Mediated Ferroptosis Defense
    Tiantian Zhang, Ziyan Cao, Kexin Gao, Shuxin Yao, Y B Zheng, Manman Cui, Rong L. Yin, Guoqiang Han, J B Hu, chengyi wang et al. · 2026 · Advanced Science
  65. Glycolysis and glycolytic enzymes in acute myeloid leukemia: Warburg and beyond
    Kristina Seiler, Yasmeen H. Mady, Bruce Edward Torbett, Jean‐Emmanuel Sarry, Mario P. Tschan · 2026 · Frontiers in Pharmacology
  66. Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution
    Zuzanna Magdalena Rzetelska, Lidia Gil, Francesco Buccisano, Dominik Dytfeld · 2026 · Journal of Cancer Research and Clinical Oncology
  67. La taurine entre dans l’arène métabolique de la niche leucémique
    Fabienne A. Brenet · 2026 · médecine/sciences
  68. Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances
    Zhengwei Tan, Jinyu Hu, Baodong Ye, Wenbin Liu · 2026 · Annals of Hematology
  69. Remodeling Metabolic Vulnerability: New Progress of Amino Acid Metabolism Pathways in the Pathogenesis and Targeted Therapy of Acute Myeloid Leukemia
    家莉 王 · 2026 · Advances in Clinical Medicine
  70. Elevated mitochondrial protein import in acute myeloid leukemia increases reliance on mitochondrial protease LONP1
    Matthew Tcheng, V. Voisin, G. Thomas, A. A. Piric, M. Gronda, R. Hurren, Da-Kai Ling, Yong-Ran Yan, Lan-Xing Zhang, Yue Feng et al. · 2026 · Journal of Clinical Investigation
  71. Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin
    Piotr Kawczak, Katarzyna Kawczak, Tomasz Bączek · 2026 · Journal of Clinical Medicine
  72. TCA-controlled histone succinylation identifies IDH3B as a prognostic and therapeutic target in AML
    Min-Hui Shi, Ke-Peng Yang, H. Ding, Na Zhao, Jie Ma, Ai-Jie Huang, Yun Wang, Xiao-Yu Zhu, Domenico Iuso, Meng-Qing Gao · 2026 · Clinical Epigenetics
  73. Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights
    Jason Charamis, Nikolaos Katzilakis, Eftichia Stiakaki, Ioannis Kyriakidis · 2026 · Cancer Chemotherapy and Pharmacology
  74. The polymerized L-phenylalanine nanocarrier overcomes TALDO1-mediated venetoclax resistance in acute myeloid leukemia
    Daosong Wang, Liying Wang, Qinghua Wei, Yuanyuan Wang, Pinggan Li, Minghui Sun, Chong He, Haipeng Chen, J R Cao, Meng Zhao et al. · 2026 · Chinese Chemical Letters
  75. RNA and Mitochondrial Reprogramming Associated with Azacytidine Treatment in Higher-Risk Myelodysplastic Syndromes: A Pilot Study
    Theodoros Nikolopoulos, Irene Dereki, Vasiliki Chondrou, Argyri Chroni, Theodora Alexiou, Katerina Athanasopoulou, Eleftherios Bochalis, Theodora Chatzilygeroudi, John Zafeiropoulos, Ilias Georgakopoulos‐Soares et al. · 2026 · Cancers
  76. Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies
    Juan Luiz Coelho‐Silva, João Agostinho Machado‐Neto · 2026 · Molecular Cancer
  77. The Dysregulation of the Integrated Stress Response in Leukemic Stem Cells as a Marker of Treatment Sensitivity in Acute Myeloid Leukemia
    Giorgia Benedetta Dutti, Katia Mangialardi, Simona Rasola, Ludovico Sebastio, Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Angela Minervini et al. · 2026 · Genes
  78. Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives
    이재복, Marc F. Diederich · 2026 · British Journal of Pharmacology
  79. Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness
    Qilong Li, Peiqi Xing, Jin Xu, Jifei Li, Liangjie Chen, Xinlu Li, 白银鹏, Gang Li, Ting Xie, Luzhen Wang et al. · 2026 · Leukemia
  80. A multi-omics integrative analyses reveals CYBB-mediated apoptotic and immune dysregulation as a key target of berberine in diffuse large B-cell lymphoma
    Jiewen Tan, Yunman Xu, Yueping He, Chang Chen, Jingwen Luo, Changxiu Zhang, Jinman Zhong, Dan Xiong · 2026 · Frontiers in Pharmacology
  81. Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia
    Clément Larrue, Paolo Angelino, Sarah Mouche, Alexa Samantha Green, Emeline Boët, Ismaël Boussaid, Claudia Pérez-Carretero, Rudy Birsen, Maxime Sajot, Thomas A. Mckee et al. · 2026 · Cell Reports Medicine
  82. Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy
    Usman Ali Shams, Fawad Inayat, Muhammad Asif Zeb, Maryam, Sulaiman Shams, Muhammad Jawad Ullah, Silvia Jiménez‐Morales · 2026 · Pharmaceuticals
  83. High-Throughput Metabolomics in Transfusion Medicine
    Travis G. Nemkov, Daniel Stephenson, Julie A. Reisz, Angelo D’Alessandro · 2026 · Methods in molecular biology
  84. Integrative single-cell and bulk transcriptomics define polyamine-associated cell states in acute myeloid leukemia and implicate CCT6A in polyamine homeostasis
    Aimei Feng, Xiaohe Chen, Fan Chen, Xiaowu Wang, Mengjia Peng, Jue Zeng, Ming Chen · 2026 · Frontiers in Immunology
  85. Dual Mitochondrial Dependencies in Cancer: OXPHOS and Fatty Acid Oxidation Pathways in Acute Myeloid Leukemia and Pancreatic Cancer; A Systematic Review and Meta-Analysis
    Mahnoor Khan, Adil Kaleem, Abu Bakar Rehman · 2026 · Journal of Biomolecules Pathogenesis and Therapeutics
  86. CC-486 plus venetoclax: another step toward oral AML therapy
    Kimberly Seymour, Marina Y Konopleva · 2026 · Blood Advances
  87. Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study
    Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa, Naoto Takahashi, Naoko Hosono et al. · 2026 · PLoS ONE
  88. Immunometabolic Reprogramming in the Bone Marrow Niche: Mechanisms, Plasticity, and Precision Therapeutic Targeting
    Adrian Khu, Alexander Parlindungan Marpaung, Princella Halim, A.Shobha Rani, Putri Cahaya Situmorang, Alexander Patera Nugraha, Fahrul Nurkolis, Rosy Iara Maciel de Azambuja Ribeiro, Bonglee Kim, Rony Abdi Syahputra · 2026 · Cell Biology International
  89. Reactive oxygen species define leukemia stem cell identity in pediatric acute myeloid leukemia
    Maddalena Benetton, Ambra Da Ros, Alberto Peloso, Giorgia Longo, Sara Perpinello, Chiara Frasson, Tiago Branco Fonseca, Elena Varotto, Silvia Bresolin, Claudia Tregnago et al. · 2026 · Cancer Letters
  90. Metabolic hallmarks of regulated cell death
    Rui Kang, Xin Chen, Guido Kroemer, Daolin Tang · 2026 · Cell Research
  91. BindingDB Entry 50019837: Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.
    BindingDB · 2024 · UC San Diego